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Abstract
Background: P-wave duration (PDURATION) and P-wave area (PAREA) have been linked 
to	risk	of	atrial	fibrillation	(AF),	but	they	do	not	improve	the	efficacy	of	Framingham	
AF	risk	score.	We	suggest	the	incorporation	of	both	variables	in	one	index,	the	P-wave	
area/P-wave duration (PAREA/DURATION)	index,	which	may	be	considered	an	expression	
of the average amplitude of the P wave that reflects aspects of P-wave morphology.
Objective: To	 assess	 the	 prognostic	 value	 of	 P-wave	 area/P-wave	 duration	 index	
(PAREA/DURATION	 index)	 in	 lead	 II	 together	with	other	P-wave	 indices	 (PWIs)	 in	 inci-
dence	of	AF	in	the	Copenhagen	Holter	Study.
Methods: The	study	included	632	men	and	women,	between	55	and	75	years	with	no	
apparent	heart	disease	or	AF.	Baseline	standard	12-lead	Electrocardiography	(ECGs)	
were analyzed manually.
Results: The	median	follow-up	time	was	14.7	(14.5;14.9)	years.	A	total	of	68	cases	
of	AF	and	233	 cases	of	 death	were	 recorded.	The	 restricted	 cubic	 spline	method	
showed a U-shaped association between PAREA/DURATION	and	rate	of	AF.	The	lowest	
quintile of PAREA/DURATION	index	in	lead	II	was	associated	with	increased	rate	of	AF,	
HR	2.80	(1.64–4.79).	The	addition	of	the	new	index	to	the	Framingham	model	for	AF	
improved the model in this population. The PAREA in lead II in its lowest quintile was 
also	associated	with	increased	rate	of	AF,	HR	2.16	(1.25–3.75),	but	did	not	improve	
the	Framingham	model.	PDURATION	and	P-wave	terminal	force	(PTF)	were	not	signifi-
cantly	associated	with	AF.
Conclusion: A	flat	P	wave	as	expressed	by	a	small	PAREA/DURATION	index	in	lead	II	is	
associated	with	increased	rate	of	incident	AF	beyond	known	AF	risk	factors.
K E Y W O R D S
atrial	fibrillation,	electrocardiography,	P	wave,	P-wave	indices
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1  | INTRODUC TION
Atrial	fibrillation	(AF)	is	the	most	common	arrhythmia	of	clinical	signif-
icance	(Kirchhof	et	al.,	2016).	AF	is	known	to	increase	cardiovascular	
and all-cause mortality as well as risk of complications such as ischemic 
stroke,	heart	failure,	and	dementia	(Kirchhof	et	al.,	2016).	Identifying	
patients	at	risk	of	developing	AF	is	important	in	preventing	AF-related	
complications,	such	as	stroke.	The	electrocardiogram	may	be	a	valu-
able	tool	in	identifying	these	patients,	as	it	is	a	cheap,	noninvasive,	and	
readily available method for evaluating electrophysiological function.
The P wave is a measure of atrial electrical activity. Previous studies 
have stipulated that P-wave indices (PWI) may be useful in determining 
which	patients	are	at	 risk	of	developing	AF	 (Aizawa,	2017;	German,	
Kabir,	 Dewland,	 Henrikson,	 &	 Tereshchenko,	 2016;	 Magnani	 et	 al.,	
2015). Such measures include P-wave duration (PDURATION),	 P-wave	
area (PAREA),	and	P-wave	terminal	force	(PTF).	PWIs	are	hypothesized	
to be surrogate measures of atrial electrical function and reflect sub-
clinical	 atrial	 remodeling	 (Magnani,	 2015).	 PDURATION is generally ac-
cepted	as	a	marker	of	atrial	conduction	time	(Conte	et	al.,	2017)	and	
both increased PDURATION	and	PTF	are	thought	to	be	markers	of	 left	
atrial	 enlargement	 (Shenasa,	 Josephson,	&	Mark	Estes,	 2015).	 PAREA 
has	been	suggested	as	a	marker	of	abnormal	atrial	structure	(German	
et	al.,	2016).	However,	studies	have	shown	varying	results	and	a	single,	
reliable	marker	for	AF	has	not	been	identified.
Abnormal	PAREA and PDURATION may be considered to reflect differ-
ent aspects of atrial structural and electrophysiological abnormalities 
(Conte	et	al.,	2017;	German	et	al.,	2016;	Shenasa	et	al.,	2015).	We	sug-
gest	 the	P-wave	 area/P-wave	duration	 index	 (PAREA/DURATION	 index),	
as	 a	 new	 P-wave	 index.	 This	 index	 can	 be	 considered	 a	 calculated	
expression	of	the	average	p-wave	amplitude,	since	 it	 is	the	ratio	be-
tween the area and the duration of the P wave. Integrating both PAREA 
and PDURATION	 in	one	single	 index	that	may	reflect	different	electro-
physiological abnormalities may provide a better measure of left atrial 
abnormalities	and	a	better	marker	of	AF.	Furthermore,	PAREA/DURATION 
reflects	 some	 aspects	 of	 the	 P-wave	 shape,	 where	 a	 small	 PAREA/
DURATION	index	may	be	considered	a	marker	for	a	flat	P	wave	and	a	large	
PAREA/DURATION	index	as	a	marker	of	a	peaked,	short	P	wave	(Figure	1).	
Recognizing these key morphological features makes it easier for clini-
cians to catch P-wave abnormalities.
The objective of the study was to evaluate the association of 
PAREA/DURATION	 index	 together	with	other	PWI,	 including	PTF,	PAREA,	
PDURATION,	and	incident	AF	in	patients	with	no	apparent	heart	disease	
at	baseline.	Furthermore,	the	study	aimed	to	investigate	the	effect	of	
adding	PWI	to	the	Framingham	AF	risk	score	(Schnabel	et	al.,	2009).
2  | METHODS
2.1 | Copenhagen Holter Study
The Copenhagen Holter Study included middle-aged and elderly 
subjects,	with	no	apparent	history	of	AF,	stroke,	or	cardiovascular	
disease,	 enrolled	 between	 April	 1998	 and	 June	 2000.	 Follow-up	
was	completed	in	2014,	with	a	median	of	approximately	14	years	of	
follow-up.	The	aim	of	the	follow-up	study	was	to	examine	the	value	
of	48-hr	Holter	recording	in	assessing	future	adverse	events	includ-
ing	AF,	ischemic	stroke,	and	mortality	in	middle-aged	and	older	men	
and women. Information about the study protocol and the selection 
process	has	been	published	previously	 (Kumarathurai	 et	 al.,	 2017;	
Larsen,	Kumarathurai,	Falkenberg,	Nielsen,	&	Sajadieh,	2015).
In	short,	all	men	of	55	years	and	all	men	and	women	of	60,	65,	
70,	and	75	years	of	age	(n	=	2,969)	living	within	2	defined	postal	re-
gions in the city of Copenhagen were contacted with a questionnaire 
regarding	 cardiovascular	 risk	 factors,	medication	 use,	 and	medical	
history. Subjects were subsequently ranked according to several 
self-reported	risk	factors	including	hypertension,	diabetes	mellitus,	
smoking	 habits,	 familial	 predisposition	 to	 sudden	 death	 or	 acute	
myocardial	infarction,	obesity	(body	mass	index	(BMI)	>	30	kg/m2),	
or	known	hypercholesterolemia.	All	responding	individuals	with	>1	
risk	 factor,	 and	60%	of	 subjects	with	0–1	 risk	 factors,	 selected	 at	
random,	were	invited	to	a	follow-up	consisting	of	a	physician-based	
questionnaire,	 physical	 examination,	 laboratory	 testing,	 electro-
cardiography	(ECG),	and	48-hr	continuous	ECG	recording.	Subjects	
with	current	or	past	AF,	manifest	ischemic	heart	disease,	congestive	
heart	failure,	valvular	heart	disease,	congenital	heart	disease,	angina	
pectoris,	 stroke,	 cancer,	 or	 other	 life-threatening	 conditions	 were	
excluded.	This	resulted	in	678	participants	who	underwent	fasting	
laboratory	tests,	a	physical	examination	with	anthropometric	mea-
surements,	baseline	ECG	and	up	to	48	hr	of	continuous	Holter	moni-
toring.	For	the	purpose	of	this	study,	out	of	the	678	participants,	648	
had	an	ECG	that	was	eligible	for	analysis.	Of	these,	16	participants	
were	excluded	because	of	missing	 variables,	 resulting	 in	632	 sub-
jects included in the analysis.
2.2 | Follow-up and endpoints
Data	 on	 death	 and	 AF	 were	 obtained	 from	 national	 registries.	
Discharge letters from hospital admissions and patient-files were 
reviewed	where	 necessary.	 Diagnosis	 of	 incident	 AF	was	 verified	
with	documentation	in	the	form	of	ECG,	telemetry	or	both	from	the	
patient records.
2.3 | Ethics
The	Copenhagen	Holter	Study	was	approved	by	the	Regional	Ethics	
Committee	of	Copenhagen	and	Frederiksberg.	The	study	complies	
with	the	Helsinki	Declaration.	All	participants	provided	their	written	
informed consent.
2.4 | ECG analysis
Baseline	 ECGs	 were	 analyzed	 manually,	 digitally	 using	 an	 image	
measurement	program	(ImageJ,	Fiji)	(Schindelin	et	al.,	2012),	divided	
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between two raters and blinded for patient outcomes. The raters 
measured	PTF	in	precordial	lead	V1 and PDURATION and PAREA in lead 
II.	A	predefined	manual	was	used	to	ensure	a	standardized	method	
of measuring by both raters.
P-wave terminal force was defined as the duration multiplied by the 
amplitude of the negative part of the P wave (P’DURATION · P’AMPLITUDE),	
measured	 in	µV	ms	 in	 lead	V1.	For	the	analysis,	 the	remaining	PWIs	
were	taken	from	measurements	in	lead	II,	as	this	lead	provides	a	good	
view	of	the	P	wave	(Meek	&	Morris,	2002).	All	P	waves	in	lead	II	were	
positive. PDURATION was measured from the on-set of the P-wave de-
flection	to	its	return	to	the	isoelectric	line,	measured	in	milliseconds.	
PAREA was measured as the area under the curve of the positive deflec-
tion	of	the	P	wave	(Figure	2).	PAREA/DURATION	index	was	calculated	as	
the ratio of PAREA and PDURATION.
The inter-rater variability was assessed by 2 raters using 20 ran-
domly	selected	ECGs.	One	rater	was	used	to	assess	intrarater	vari-
ability,	measuring	 the	same	20	ECGs	 twice.	 In	addition,	 inter-rater	
variability was compared with automated measures.
2.5 | Statistics
Continuous variables are presented as median and interquartile 
range (IQR) and compared with Kruskal-Wallis tests. Categorical var-
iables are presented as frequency (percentage) and compared with 
chi-square tests. Two-tailed tests of significance are reported and 
the	level	of	statistical	significant	was	set	at	5%.	The	reproducibility	
was	assessed	for	intra-,	inter	and	manual-automatic	variability	using	
interclass correlation coefficient (ICC).
The Kaplan-Meier method was used to calculate the absolute risk 
of	all-cause	mortality	and	the	Aalen-Johansen	method	to	calculate	the	
absolute	risk	of	AF.	The	association	between	PWI	and	the	AF-hazard	
rate	was	analyzed	by	cause-specific	Cox	regression.	To	allow	that	ex-
tremely	 low	and	extremely	high	values	of	 a	biomarker	both	 can	be	
associated	with	 increased	AF-hazard	rate,	we	categorized	the	mark-
ers PAREA/DURATION	 index	and	PAREA	according	to	their	20%	and	80%	
quintiles.	Reported	were	two	AF-hazard	ratios	and	all-cause	mortality	
hazard	 ratios	with	95%	confidence	 limits	 (CI)	 using	 the	middle	60%	
of	the	marker	values	as	reference.	All	analyses	with	AF	as	endpoint	
were	adjusted	for	Framingham	score	variables	(Schnabel	et	al.,	2009).	
All-cause	mortality	was	adjusted	for	age,	sex,	smoking,	diabetes	mel-
litus,	and	systolic	blood	pressure.	To	graphically	illustrate	the	relation	
between	 PWI	 and	AF-hazard	 rate,	we	 also	 applied	 restricted	 cubic	
splines	with	three	knots	(Harrell,	2001).	For	prediction	analysis	area	
under	the	ROC	curve	(AUC),	we	used	the	categorized	P-wave	param-
eters. PDURATION	and	PTF	were	categorized	by	known	cut	off	points	
F I G U R E  1  Examples	of	P-wave	shape	in	quintiles	of	P-wave	area/P-wave	duration	index	in	lead	II.	The	figure	shows	examples	of	P-wave	
shape	taken	from	the	included	electrocardiography	s	in	this	study,	divided	into	5	quintiles.	The	index	is	a	representation	of	the	average	
amplitude	of	the	P	wave.	A	small	index	(Q1)	arises	when	the	ratio	between	area	and	duration	is	skewed	and	the	denominator	is	larger	relative	
to	the	numerator,	meaning	a	longer	P-wave	duration	and	a	smaller	P-wave	area,	hence,	a	flat,	prolonged	P	wave.	A	large	index	(Q5)	is	a	
representation	of	a	ratio	with	a	small	denominator	and	a	large	numerator,	being	a	short,	peaked	P	wave.	The	3	middle	quintiles	represent	
normal P waves where the ratio between P-wave area and P-wave duration is not skewed
F I G U R E  2  P-wave	measurements	in	lead	V1 and II. P-wave 
indices	were	measured	digitally,	manually	in	leads	V1 and II. P-wave 
terminal	force	was	measured	in	lead	V1 as the duration multiplied 
by	the	amplitude	of	the	negative	part	of	the	P	wave	(µV	ms).	
P-wave	area	(µV	ms),	P-wave	duration	(ms),	and	PR-interval	(ms)	
were measured in lead II
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from literature (PDURATION	>	120	ms	and	PTF	>	4,000	µV	ms)	(Magnani	
et	al.,	2010).
R	Core	Team	(2018)	and	StataCorp	(2013)	were	used	for	statis-
tical analysis.
3  | RESULTS
The	study	 included	632	participants	with	no	apparent	heart	dis-
ease at baseline. Table 1 shows the baseline characteristics for 
the overall study population and for three groups of the PAREA/
DURATION	index	in	lead	II,	divided	into	the	lowest	quintile,	the	three	
middle	quintiles	joined	(20%–80%)	and	the	highest	quintile	of	the	
index.	PAREA/DURATION	 index	 in	the	 lower	quintiles	was	associated	
with	 lower	 heart	 rate,	 and	 with	 smaller	 other	 PWIs	 in	 general.	
Apart	from	these	differences,	the	groups	were	comparable	in	rela-
tion	to	other	known	risk	factors	of	AF.	Median	follow-up	time	was	
14.7	 (14.5;14.9)	 years.	 During	 this	 time,	 there	were	 68	 cases	 of	
incident	AF	and	233	deaths.
3.1 | Association analyses
AF: PAREA/DURATION	 index	 and	 PAREA were both associated with in-
creased	rate	of	AF	in	their	lowest	quintiles	(Table	2).	PDURATION and 
PTF	were	not	associated	with	rate	of	AF	in	these	analyses.	Adding	
heart	 rate	 to	 the	 cox	 regression	models	 did	 not	 alter	 the	 results.	
Restricted cubic spline analyses showed a U-shaped association be-
tween PAREA/DURATION	and	risk	of	AF.	However,	the	highest	quintile	
did	not	reach	statistical	significance	(Figure	3).
TA B L E  1  Baseline	characteristics	of	study	participants	and	comparison	of	characteristics	in	groups	of	lowest	quintile,	Q20-Q80	and	
highest	quintile	of	P-wave	area/P-wave	duration	index	in	lead	II
Variable Level
Lowest quintile 
(n = 127)
Q20-Q80 
(n = 378)
Highest quintile 
(n = 127) Total (n = 632) p-value
Gender Male 77	(60.6) 220	(58.2) 68	(53.5) 365	(57.8) .50
Age 55 35	(27.6) 73	(19.3) 20 (15.7) 128	(20.3)  
60 28	(22.0) 88	(23.3) 30	(23.6) 146	(23.1)  
65 18	(14.2) 83	(22.0) 33	(26.0) 134	(21.2)  
70 23	(18.1) 76	(20.1) 24	(18.9) 123	(19.5)  
75 23	(18.1) 58	(15.3) 20 (15.7) 101	(16.0) .27
BMI Underweight 1	(0.8) 6	(1.6) 5	(3.9) 12 (1.9)  
Normal 32	(25.2) 125	(33.1) 55	(43.3) 212	(33.5)  
Overweight 63	(49.6) 177	(46.8) 50	(39.4) 290 (45.9)  
Obese 31	(24.4) 70	(18.5) 17	(13.4) 118	(18.7) .01
Smoker Yes 62	(48.8) 171 (45.2) 62	(48.8) 295	(46.7) .68
Systolic	Blood	pressure,	
mmHg
 155	[30]
(120,	220)
150	[30]
(100,	235)
160	[40]
(100,	250)
155	[30]
(100,	250)
.20
Heart	rate,	beats	pr.	min  66	[12]
(48,	95)
70.5	[15.8]
(48,	107)
78	[15.5]
(49,	112)
71	[16]
(48,	112)
<.0001
Systolic murmur Grade	0 86	(67.7) 252	(66.7) 84	(66.1) 422	(66.8)  
Grade	1–2 36	(28.3) 119	(31.5) 40	(31.5) 195	(30.9)  
Grade	3–4 5	(3.9) 7 (1.9) 3	(2.4) 15 (2.4) .87
Diabetes Present 13	(10.2) 44	(11.6) 13	(10.2) 70 (11.1) .86
Hypertension treatment Present 34	(26.8) 105	(27.8) 39	(30.7) 178	(28.2) .76
Cholesterol  6	[1.3]
(2.5,	8.4)
6	[1.4]
(3.3,	11.0)
6.1	[1.4]
(1.9,	8.4)
6	[1.3]
(1.9,	11.0)
.52
PR-interval  163.3	[30]
(121.7,	226.7)
165	[25]
(115,	275)
163.3
[20.8]	(123.3,	240.0)
165	[25]
(115,	275)
.83
P-wave	area,	lead	II	
(µV·ms)
 4,781	[1688]
(1,063,	11,656)
8,438	[2422]
(4,094,	14,063)
11,969	[2531]
(7,844,	17,313)
8,453	[4143]
(1,063,	17,313)
<.001
P-wave	duration,	lead	
II (ms)
 91	[26]
(35,	128)
106	[18]
(63,	149)
106	[12]
(56,	143)
104	[18]
(35,	149)
<.001
P-wave	terminal	force,	
lead	V1	(µV·ms)
 2,798	[1939]	(506,	
8,779)
3,918	[2334]	
(737,	11,559)
5,840	[4064]	(670,	
18,926)
3,937	[2743]	
(506,	18,926)
<.001
Note: Values	are	n	(%)	or	median	interquartile	range	[IQR]	(range).
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Mortality: PAREA/DURATION	index	in	its	highest	quintile	was	associ-
ated	with	mortality	(Table	2).	None	of	the	other	PWI	were	associated	
with mortality.
3.2 | Discrimination
The addition of PAREA/DURATION	 index	 significantly	 improved	 AF	
risk discrimination after 15 years of follow-up. Receiver Operating 
Characteristic	analyses	 (AUC)	 for	 the	Framingham	score	variables,	
different	PWI,	and	addition	of	PWI	into	the	Framingham	model	are	
shown	in	Table	3.
3.3 | Absolute risk
Figure	 4	 shows	 Aalen-Johansen	 curves	 for	 the	 events	 of	 AF	 and	
Figure	5	 show	Kaplan-Meier	 survival	 curves	 for	 the	 events	 of	 all-
cause mortality for different PAREA/DURATION categories.
3.4 | Inter- and intrarater variability for P-wave 
measurement
The intraobserver reliability for PDURATION,	PAREA,	and	PTF	had	ICC	
values	of	.96,	.99,	and	.99,	respectively.	The	interobserver	reliability	
for two observers for PDURATION,	PAREA,	and	PTF	had	ICC	values	of	
.94,	 .96,	 and	 .97,	 respectively.	We	 also	 investigated	 the	 variability	
between	manual	and	automated	ECG	analysis,	with	 ICC	values	for	
PDURATION	and	PTF	of	0.89	and	0.88,	respectively.
4  | DISCUSSION
This	was	an	exploratory	study	that	aimed	to	assess	the	prognostic	
value of the PAREA/DURATION	 index	and	other	PWI	 in	 incidence	of	
AF	The	major	finding	of	this	study	is	that	a	flat	P	wave	(Figure	1)	
expressed	as	a	small	PAREA/DURATION	index	in	lead	II,	is	significantly	
associated	with	 long-term	 incidence	of	AF	 after	 relevant	 adjust-
ments.	Furthermore,	 it	was	 shown	 that	 the	PAREA/DURATION	 index	
improved	 the	 Framingham	 risk	 model	 for	 AF	 in	 this	 population.	
An	 increased	PAREA/DURATION	 index	was	associated	with	all-cause	
mortality.
Many cardiovascular diseases and concomitant conditions in-
crease	the	risk	of	developing	AF	(Kirchhof	et	al.,	2016).	Cumulative	
exposure	to	risk	factor	induces	a	progressive	structural	remodel-
ing	of	the	atria	 (Kirchhof	et	al.,	2016).	The	hallmark	of	structural	
atrial	 remodeling	 in	 the	progressive	process	of	AF	 is	atrial	 fibro-
sis	and	dilatation	 (Kirchhof	et	al.,	2016).	Fibrosis	seems	to	be	an	
important	underlying	cause	of	AF	because	of	conduction	hetero-
geneity,	triggered	activity,	and	reentry	(Burstein	&	Nattel,	2008).	
Histologically,	the	atrial	tissue	in	patients	with	AF	is	shown	to	be	
more	 fibrotic	 compared	 to	 atrial	 tissue	 in	 patients	 without	 AF	
(Burstein	&	Nattel,	 2008).	 Increased	 fibrotic	 tissue,	 loss	of	mus-
cle,	and	dilatation	of	the	atria	are	correlated	to	more	frequent	and	
less	 reversible	 incidents	of	AF	 (Burstein	et	 al.,	 2008).	Prolonged	
total atrial activation time is an indirect marker of atrial fibrosis 
(Gorenek	et	al.,	2017).	Fibrosis	 is	known	to	decrease	conduction	
(Nguyen,	Qu,	&	Weiss,	2014),	thereby	giving	a	smaller	and	longer	
signal	on	the	ECG	(Michelucci	et	al.,	2002).	A	small	PAREA/DURATION 
index	may,	 therefore,	 be	 considered	 a	 possible	 marker	 for	 both	
atrial	dilatation	and	fibrosis.	These	changes	can	prolong	LA's	acti-
vation time and thus be considered as the equivalent of left bun-
dle branch block and poor R-wave progression in the ventricles. 
These changes may be due to increased pressure or volume load 
on	 atrium,	 for	 example,	 due	 to	 hypertension	 or	 valvular	 disease	
or a slow degeneration due to genetic factors or environmental 
factors.
It is noteworthy that the effect of PAREA/DURATION on the risk of 
AF	 could	 be	 demonstrated	 only	 after	 several	 years	 of	 follow-up.	
Thus,	 a	 smaller	 PAREA/DURATION may represent initial atrial changes 
that	after	years	will	 lead	to	AF.	Another	possibility	 is	that	many	of	
these	subjects	have	had	undetected	paroxysmal	AF	for	years	before	
it was ultimately incident.
The association of PAREA/DURATION in its highest quintile and in-
creased rate of mortality is also notable and may be due to dilatation 
TA B L E  2  Association	of	P-wave	indices	with	adjusted	hazard	rates	for	AF	and	mortality
P-wave indices AF (HR) 95% CI p-value Mortality (HR) 95% CI p-value
P-wave	area/P-wave	duration	index,	lead	II	
(Lowest	quintilea)
2.80 (1.64,4.79) <.001 1.17 (0.84,1.63) .36
P-wave	area/P-wave	duration	index,	lead	II	
(highest quintilea)
1.25 (0.64,2.46) .52 1.39 (1.01,1.92) .04
P-wave	area,	lead	II	(Lowest	quintilea) 2.16 (1.25,3.75) .006 1.03 (0.73,1.44) .88
P-wave	area,	lead	II	(highest	quintilea) 1.03 (0.54,1.97) .93 1.06 (0.76,1.47) .75
P-wave	duration,	lead	II	above	120	ms 1.81 (0.95,3.45) .07 1.03 (0.68,1.56) .88
P-wave	terminal	force	V1	above	4,000 0.86 (0.52,1.41) .55 1.03 (0.79,1.34) .85
Note: Atrial	fibrillation	(AF)	adjusted	for	Framingham	AF	risk	factors:	age,	gender,	systolic	blood	pressure,	body	mass	index,	PR-interval,	and	systolic	
murmur.	Mortality	adjusted	for	age,	gender,	smoking,	systolic	blood	pressure,	cholesterol,	and	diabetes.
aCompared	with	quintile	2–4	as	references.	
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and hypertrophy of atrium due to other diseases with increased 
work	load	on	the	atria,	such	as	pulmonary	artery	hypertension,	se-
vere	hypertension,	or	similar.
Our findings are consistent with previous research that has 
demonstrated a significant association between a small PAREA and 
rate	 of	 AF	 (Magnani	 et	 al.,	 2015).	 However,	 PAREA has not been 
widely	investigated.	To	our	knowledge,	only	two	other	studies	have	
examined	PAREA	in	relation	to	AF	risk.	The	ARIC	study	showed	that	
both	 large	and	 small	maximum	PAREA were significantly associated 
with	AF	 (Magnani	et	al.,	2015).	The	Framingham	study	showed	no	
increased	risk	associated	with	maximum	PAREA	(Magnani	et	al.,	2015).	
In	fact,	the	Framingham	study	found	no	increased	AF	risk	associated	
with any PWIs. Other studies have shown that prolonged PDURATION 
is	associated	with	AF	(Magnani	et	al.,	2011),	and	one	study	has	found	
that shorter PDURATION	(Nielsen	et	al.,	2015)	is	also	significantly	asso-
ciated	with	AF.	The	associations	for	PAREA and PDURATION in relation 
to	AF	 risk	 can	 therefore	 possibly	 also	 be	 considered	 as	U-shaped	
curves,	 where	 both	 smaller	 and	 larger	 than	 normal	 measures	 are	
signs	 of	 atrial	 dysfunction	 and	 thereby	 possible	 predictors	 of	 AF.	
This	 is	 also	 clear	 from	 restricted	 cubic	 spline	 curves	 in	 this	 study,	
showing a U-shaped trend for the PAREA/DURATION	 index,	 however,	
with	a	broad	confidence	interval	in	the	high	end,	possibly	due	to	too	
few observations.
In	 contrast	 to	 previous	 studies,	 however,	 we	 found	 no	 asso-
ciation	between	PTF	and	 rate	of	AF.	PTF	 is	particularly	 sensitive	
to	 electrode	 placement	 (Rasmussen	 et	 al.,	 2019).	 Therefore,	 the	
F I G U R E  3  Restricted	cubic	splines	of	Hazard	rate	for	atrial	fibrillation	(AF)	and	P-wave	indices.	Restricted	cubic	spline	analysis	of	the	
P-wave	area/P-wave	duration	index	and	other	PWI	in	relation	to	the	hazard	ratio	of	AF
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lack of association in this study may in part be due to the occur-
rence of high placement of the precordial electrodes in clinical 
settings	 (García-Niebla,	 2009;	 McCann,	 Holdgate,	 Mahammad,	
&	Waddington,	 2007;	 Medani,	 Hensey,	 Caples,	 &	 Owens,	 2017;	
Rajaganeshan,	Ludlam,	Francis,	Parasramka,	&	Sutton,	2008),	and	
the impact that high placement has on measurements. High place-
ment	of	V1-V2 electrodes increases the negative component of the 
P	wave	in	V1	and	V2	(García-Niebla,	2009;	Ishikawa	&	Yanagisawa,	
1981).	 In	 this	study,	other	PWI	has	been	measured	 in	 lead	 II.	We	
argue	that	the	limb	leads	are	most	reliable	for	measuring	PWI.	Lead	
P-wave indices
Years since 
electrocardiography AUC (CI) Delta AUC (CI) p
Framingham	variables	
alone
5 78.0	[70.2;85.8]   
P-wave area/P-wave 
duration	index,	
lead II
5 78.6	[70.4;86.9] 0.6	[−8.2;9.4] .89
P-wave	area,	lead	II 5 78.1	[70.4;85.8] 0.1	[−7.4;7.6] .98
P-wave	duration,	
lead II
5 77.6	[68.1;87.1] −0.4	[−3.5;2.7] .80
P-wave terminal 
force,	lead	V1
5 77.7	[69.4;86.0] −0.3	[−2.4;1.8] .78
Framingham	variables	
alone
15 53.5	[29.1;77.9]   
P-wave area/P-wave 
duration	index,	
lead II
15 62.0	[33.6;90.3] 8.5	[0.6;16.3] .034
P-wave	area,	lead	II 15 59.1	[32.3;85.9] 5.6	[−0.6;11.8] .076
P-wave	duration,	
lead II
15 54.8	[29.7;79.8] 1.3	[−1.7;4.3] .41
P-wave terminal 
force,	lead	V1
15 54.4	[29.6;79.2] 0.9	[−0.9;2.8] .33
Note: Area	under	the	ROC	curve	for	P-wave	area/P-wave	duration	index	and	other	PWI	when	
added	to	Framingham	score	variables.
TA B L E  3   Difference in area under 
the	ROC	curve	(AUC)	in	relation	to	
atrial	fibrillation	with	Framingham	score	
variables alone versus addition of P-wave 
indices for 5 and 15 years of follow-up
F I G U R E  4  Absolute	risk	of	atrial	fibrillation	(AF)	by	P-wave	
area/P-wave	duration	index	in	three	groups.	Absolute	risk	of	AF	
in	years	since	baseline	electrocardiography	divided	into	lowest,	
highest,	and	middle	quintiles	for	the	PAREA/DURATION	index
F I G U R E  5  Absolute	risk	of	mortality	for	P-wave	area/P-wave	
duration	index.	Absolute	risk	of	mortality	in	years	since	baseline	
electrocardiography	divided	into	lowest,	highest,	and	middle	
quintiles for the PAREA/DURATION	index
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II	is	known	to	be	the	best	lead	for	evaluating	P	waves	(Meek	et	al.,	
2002).
4.1 | Limitations
Our	study	sample	was	comprised	mostly	of	Caucasians,	so	our	re-
sults	may	not	be	transferrable	to	other	ethnic	groups.	Furthermore,	
our	 sample	 consisted	of	 subjects	 over	55	 years	 of	 age,	most	with	
at	 least	 one	 cardiovascular	 risk	 factor,	 so	 our	 results	 may	 not	 be	
transferrable	to	a	younger,	healthy	population.	Additionally,	there	is	
a	possibility	that	not	all	cases	of	AF	were	recorded,	because	of	the	
paroxysmal	nature	of	this	arrhythmia.
In	 this	 study,	 automated	 analysis	 and	 quantification	 were	 not	
performed;	however,	we	have	demonstrated	that	PWI	can	be	mea-
sured manually with high intra and inter-rater reproducibility that 
correlate well with automated measurements.
4.2 | Clinical perspective
AF	 prediction	 using	 simple,	 clinically	 available	 tools	 that	 enable	
clinicians to identify subjects with increased risk of developing 
AF	would	be	of	high	value	in	pre-emptive	strategies	of	AF-related	
complications. Our study is consistent with previous studies that 
suggest	PWI	could	be	a	potential	candidate,	and	we	demonstrated	
that	the	new	index	(PAREA/DURATION) is a strong marker with addi-
tive	effect	on	Framingham	AF	score	and	an	association	with	all-
cause	mortality.	However,	further	studies	are	necessary	 in	order	
to	 establish	 the	 reliability	 of	 this	 new	 index	 as	 a	marker	 for	 AF	
prediction.	As	PAREA/DURATION also reflects aspects of P-wave mor-
phology,	 it	makes	 it	 easier	 for	 clinicians	 to	visualize	 and	capture	
P-wave abnormalities.
5  | CONCLUSION
A	flat	P	wave	as	expressed	by	a	small	PAREA/DURATION	 index	 in	 lead	
II,	possibly	as	an	ECG	marker	of	atrial	muscle	loss	and	prolongation	
of	conduction	time,	is	associated	with	increased	rate	of	incident	AF	
beyond	known	AF	risk	factors.
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